IQGAP3 promotes cancer proliferation and metastasis in high‑grade serous ovarian cancer

Dongol,Samina; Zhang,Qing; Qiu,Chunping; Sun,Chenggong; Zhang,Zhiwei; Wu,Huan; Kong,Beihua

doi:10.3892/ol.2020.11664

IQGAP3 promotes cancer proliferation and metastasis in high‑grade serous ovarian cancer

Authors:
- Samina Dongol
- Qing Zhang
- Chunping Qiu
- Chenggong Sun
- Zhiwei Zhang
- Huan Wu
- Beihua Kong
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Ji'nan, Shandong 250012, P.R. China
Published online on: May 21, 2020 https://doi.org/10.3892/ol.2020.11664
Pages: 1179-1192
Copyright: © Dongol et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is a type of gynecological cancer with the highest mortality rate worldwide. Due to a lack of effective screening methods, most cases are diagnosed at later stages where the survival rates are poor. Thus, it is termed a ‘silent killer’ and is the most lethal of all the malignancies in women. IQ motif containing GTPase Activating Protein 3 (IQGAP3) is a member of the Rho family of GTPases, and plays a crucial role in the development and progression of several types of cancer. The aim of the present study was to investigate the oncogenic functions and mechanisms of IQGAP3 on the proliferation and metastasis of high‑grade serous ovarian cancer (HGSOC). Therefore, the expression levels of IQGAP3 in HGSOC and normal tissue samples were compared, and IQGAP3 knockdown was performed to examine its functional role using various in vitro and in vivo experiments. It was demonstrated that the expression of IQGAP3 was upregulated in HGSOC tissues compared with the healthy tissues; this differential expression was also observed in the ovarian cancer cell lines. Functional experimental results suggested that IQGAP3 silencing significantly reduced proliferation, migration and invasion in ovarian cancer cell lines. Moreover, in vivo experimental findings validated the in vitro results, where the tumorigenic and metastatic capacities of IQGAP3‑silenced cells were significantly lower in the nude mice compared with the mice implanted with the control cells. Furthermore, knockdown of IQGAP3 resulted in increased apoptosis, and the effects of IQGAP3 expression on various epithelial‑mesenchymal transition markers were identified, suggesting a possible mechanism associated with the role of IQGAP3 in metastasis. The effect of IQGAP3 silencing on chemosensitivity towards olaparib was also assessed. Collectively, the present results indicated that IQGAP3 is a potential diagnostic and prognostic marker, and a putative therapeutic target of HGSOC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Cancer Stat Facts: Ovarian Cancer. 2019. PubMed/NCBI
3	Ozols RF: Systemic therapy for ovarian cancer: Current status and new treatments. Semin Oncol. 33 (Suppl 6):S3–S11. 2006. View Article : Google Scholar : PubMed/NCBI
4	Karnezis AN, Cho KR, Gilks CB, Pearce CL and Huntsman DG: The disparate origins of ovarian cancers: Pathogenesis and prevention strategies. Nat Rev Cancer. 17:65–74. 2017. View Article : Google Scholar : PubMed/NCBI
5	Cho KR and Shih IeM: Ovarian cancer. Annu Rev Pathol. 4:287–313. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kurman RJ and Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol. 34:433–443. 2010. View Article : Google Scholar : PubMed/NCBI
7	Bast RC Jr, Hennessy B and Mills GB: The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI
8	Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ and Ronnett BM: The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 23:41–44. 2004. View Article : Google Scholar : PubMed/NCBI
9	Peres LC, Cushing-Haugen KL, Köbel M, Harris HR, Berchuck A, Rossing MA and Doherty JA: Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst. 111:60–68. 2019. View Article : Google Scholar : PubMed/NCBI
10	Pilié PG, Tang C, Mills GB and Yap TA: State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 16:81–104. 2019. View Article : Google Scholar : PubMed/NCBI
11	AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, et al: In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecol Oncol. 143:379–388. 2016. View Article : Google Scholar : PubMed/NCBI
12	McGuire WP III and Markman M: Primary ovarian cancer chemotherapy: Current standards of care. Br J Cancer. 89 (Suppl 3):S3–S8. 2003. View Article : Google Scholar : PubMed/NCBI
13	Pokhriyal R, Hariprasad R, Kumar L and Hariprasad G: Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer. 11:1179299X198608152019. View Article : Google Scholar : PubMed/NCBI
14	Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, et al: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 379:2495–2505. 2018. View Article : Google Scholar : PubMed/NCBI
15	Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, et al: FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 21:4257–4261. 2015. View Article : Google Scholar : PubMed/NCBI
16	Briggs MW and Sacks DB: IQGAP proteins are integral components of cytoskeletal regulation. EMBO Rep. 4:571–574. 2003. View Article : Google Scholar : PubMed/NCBI
17	Weissbach L, Settleman J, Kalady MF, Snijders AJ, Murthy AE, Yan YX and Bernards A: Identification of a human rasGAP-related protein containing calmodulin-binding motifs. J Biol Chem. 269:20517–20521. 1994.PubMed/NCBI
18	Hedman AC, Smith JM and Sacks DB: The biology of IQGAP proteins: Beyond the cytoskeleton. EMBO Rep. 16:427–446. 2015. View Article : Google Scholar : PubMed/NCBI
19	Swart-Mataraza JM, Li Z and Sacks DB: IQGAP1 is a component of Cdc42 signaling to the cytoskeleton. J Biol Chem. 277:24753–24763. 2002. View Article : Google Scholar : PubMed/NCBI
20	Sahai E and Marshall CJ: RHO-GTPases and cancer. Nat Rev Cancer. 2:133–142. 2002. View Article : Google Scholar : PubMed/NCBI
21	Tang Y, Olufemi L, Wang MT and Nie D: Role of Rho GTPases in breast cancer. Front Biosci. 13:759–776. 2008. View Article : Google Scholar : PubMed/NCBI
22	Erickson JW and Cerione RA: Multiple roles for Cdc42 in cell regulation. Curr Opin Cell Biol. 13:153–157. 2001. View Article : Google Scholar : PubMed/NCBI
23	Arias-Romero LE and Chernoff J: Targeting Cdc42 in cancer. Expert Opin Ther Targets. 17:1263–1273. 2013. View Article : Google Scholar : PubMed/NCBI
24	Johnson M, Sharma M and Henderson BR: IQGAP1 regulation and roles in cancer. Cell Signal. 21:1471–1478. 2009. View Article : Google Scholar : PubMed/NCBI
25	Mataraza JM, Briggs MW, Li Z, Entwistle A, Ridley AJ and Sacks DB: IQGAP1 promotes cell motility and invasion. J Biol Chem. 278:41237–41245. 2003. View Article : Google Scholar : PubMed/NCBI
26	Schmidt VA, Chiariello CS, Capilla E, Miller F and Bahou WF: Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol Cell Biol. 28:1489–1502. 2008. View Article : Google Scholar : PubMed/NCBI
27	Nojima H, Adachi M, Matsui T, Okawa K and Tsukita S and Tsukita S: IQGAP3 regulates cell proliferation through the Ras/ERK signalling cascade. Nat Cell Biol. 10:971–978. 2008. View Article : Google Scholar : PubMed/NCBI
28	Wang S, Watanabe T, Noritake J, Fukata M, Yoshimura T, Itoh N, Harada T, Nakagawa M, Matsuura Y, Arimura N and Kaibuchi K: IQGAP3, a novel effector of Rac1 and Cdc42, regulates neurite outgrowth. J Cell Sci. 120:567–577. 2007. View Article : Google Scholar : PubMed/NCBI
29	Yang Y, Zhao W, Xu QW, Wang XS, Zhang Y and Zhang J: IQGAP3 promotes EGFR-ERK signaling and the growth and metastasis of lung cancer cells. PLoS One. 9:e975782014. View Article : Google Scholar : PubMed/NCBI
30	Hu G, Xu Y, Chen W, Wang J, Zhao C and Wang M: RNA Interference of IQ motif containing GTPase-activating protein 3 (IQGAP3) inhibits cell proliferation and invasion in breast carcinoma cells. Oncol Res. 24:455–461. 2016. View Article : Google Scholar : PubMed/NCBI
31	Shi Y, Qin N, Zhou Q, Chen Y, Huang S, Chen B, Shen G and Jia H: Role of IQGAP3 in metastasis and epithelial-mesenchymal transition in human hepatocellular carcinoma. J Transl Med. 15:1762017. View Article : Google Scholar : PubMed/NCBI
32	Cao H, Wang Q, Gao Z, Xu X, Lu Q and Wu Y: Clinical value of detecting IQGAP3, B7-H4 and cyclooxygenase-2 in the diagnosis and prognostic evaluation of colorectal cancer. Cancer Cell Int. 19:1632019. View Article : Google Scholar : PubMed/NCBI
33	Wu J, Chen Z, Cao H, Yu Z, Feng J, Wang K, Lu Q and Wu Y: High expression of IQGAP3 indicates poor prognosis in colorectal cancer patients. Int J Biol Markers. 34:348–355. 2019. View Article : Google Scholar : PubMed/NCBI
34	Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y and Oue N: Molecular pathology of gastric cancer: Research and practice. Pathol Res Pract. 207:608–612. 2011. View Article : Google Scholar : PubMed/NCBI
35	Xu W, Xu B, Yao Y, Yu X, Cao H, Zhang J, Liu J and Sheng H: Overexpression and biological function of IQGAP3 in human pancreatic cancer. Am J Transl Res. 8:5421–5432. 2016.PubMed/NCBI
36	Javadi S, Ganeshan DM, Qayyum A, Iyer RB and Bhosale P: Ovarian cancer, the revised FIGO staging system, and the role of imaging. AJR Am J Roentgenol. 206:1351–1360. 2016. View Article : Google Scholar : PubMed/NCBI
37	Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS and Mok SC: Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol. 25:2281–2287. 2007. View Article : Google Scholar : PubMed/NCBI
38	Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P, Sastre-Garau X and Mechta-Grigoriou F: miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 17:1627–1635. 2011. View Article : Google Scholar : PubMed/NCBI
39	Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodorescu D and Lee JK: Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: Predicting platinum resistance. PLoS One. 7:e305502012. View Article : Google Scholar : PubMed/NCBI
40	Lisowska KM, Olbryt M, Dudaladava V, Pamuła-Piłat J, Kujawa K, Grzybowska E, Jarzab M, Student S, Rzepecka IK, Jarzab B and Kupryjańczyk J: Gene expression analysis in ovarian cancer-faults and hints from DNA microarray study. Front Oncol. 4:62014. View Article : Google Scholar : PubMed/NCBI
41	Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
42	Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, et al: Integrated copy number and expression analysis identifies profiles of Whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas. PLoS One. 10:e01280662015. View Article : Google Scholar : PubMed/NCBI
43	Gyorffy B, Lánczky A and Szállási Z: Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012. View Article : Google Scholar : PubMed/NCBI
44	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
45	Pokharel D, Roseblade A, Oenarto V, Lu JF and Bebawy M: Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer. Ecancermedicalscience. 11:7682017. View Article : Google Scholar : PubMed/NCBI
46	Naora H and Montell DJ: Ovarian cancer metastasis: Integrating insights from disparate model organisms. Nat Rev Cancer. 5:355–366. 2005. View Article : Google Scholar : PubMed/NCBI
47	Campos SM and Ghosh S: A current review of targeted therapeutics for ovarian cancer. J Oncol. 149362:2010.
48	Hogberg T: Chemotherapy: Current drugs still have potential in advanced ovarian cancer. Nat Rev Clin Oncol. 7:191–193. 2010. View Article : Google Scholar : PubMed/NCBI
49	White CD, Khurana H, Gnatenko DV, Li Z, Odze RD, Sacks DB and Schmidt VA: IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma. BMC Gastroenterol. 10:1252010. View Article : Google Scholar : PubMed/NCBI
50	Wu K, Zhang X, Li F, Xiao D, Hou Y, Zhu S, Liu D, Ye X, Ye M, Yang J, et al: Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun. 6:101312015. View Article : Google Scholar : PubMed/NCBI
51	Guan X: Cancer metastases: Challenges and opportunities. Acta Pharm Sin B. 5:402–418. 2015. View Article : Google Scholar : PubMed/NCBI
52	Huang RY, Chung VY and Thiery JP: Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. Curr Drug Targets. 13:1649–1653. 2012. View Article : Google Scholar : PubMed/NCBI
53	Berx G, Raspe E, Christofori G, Thiery JP and Sleeman JP: Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis. 24:587–597. 2007. View Article : Google Scholar : PubMed/NCBI
54	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
55	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
56	Barrallo-Gimeno A and Nieto MA: The Snail genes as inducers of cell movement and survival: Implications in development and cancer. Development. 132:3151–3161. 2005. View Article : Google Scholar : PubMed/NCBI
57	Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
58	Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
59	Cantley LC: The phosphoinositide 3-kinase pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
60	Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
61	Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P and Bouscary D: PI3K and mTOR signaling pathways in cancer: New data on targeted therapies. Curr Oncol Rep. 14:129–138. 2012. View Article : Google Scholar : PubMed/NCBI
62	McAuliffe P, Meric-Bernstam F, Mills GB and Gonzalez-Angulo A: Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer. 10 (Suppl 3):S59–S65. 2010. View Article : Google Scholar : PubMed/NCBI
63	Gasparri ML, Bardhi E, Ruscito I, Papadia A, Farooqi AA, Marchetti C, Bogani G, Ceccacci I, Mueller MD and Benedetti Panici P: PI3K/AKT/mTOR pathway in ovarian cancer treatment: Are we on the right track? Geburtshilfe Frauenheilkd. 77:1095–1103. 2017. View Article : Google Scholar : PubMed/NCBI
64	Mabuchi S, Kuroda H, Takahashi R and Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
65	Wong RS: Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011. View Article : Google Scholar : PubMed/NCBI
66	Su Z, Yang Z, Xu Y, Chen Y and Yu Q: Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer. 14:482015. View Article : Google Scholar : PubMed/NCBI
67	Melendez J, Grogg M and Zheng Y: Signaling role of Cdc42 in regulating mammalian physiology. J Biol Chem. 286:2375–2381. 2011. View Article : Google Scholar : PubMed/NCBI
68	Morgan CJ, Hedman AC, Li Z and Sacks DB: Endogenous IQGAP1 and IQGAP3 do not functionally interact with Ras. Sci Rep. 9:110572019. View Article : Google Scholar : PubMed/NCBI
69	Ramus SJ and Gayther SA: The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 3:138–150. 2009. View Article : Google Scholar : PubMed/NCBI
70	Jiang X, Li X, Li W, Bai H and Zhang Z: PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med. 23:2303–2313. 2019. View Article : Google Scholar : PubMed/NCBI